GRDN vs CCRN

For growth investors, Guardian Pharmacy Services, Inc.

(GRDN) is the stronger pick with 17. 9% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). Guardian Pharmacy Services, Inc. (GRDN) offers the better valuation at 46. 5x trailing P/E (29. 6x forward), making it the more compelling value choice. Analysts rate Guardian Pharmacy Services, Inc. (GRDN) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Guardian Pharmacy Services, Inc.

is actually cheaper at 29. 6x.

Over the past 5 years, Guardian Pharmacy Services, Inc.

(GRDN) delivered a total return of +126. 8%, compared to -22. 5% for Cross Country Healthcare, Inc. (CCRN). Over 10 years, the gap is even starker: GRDN returned +126. 7% versus CCRN's -10. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cross Country Healthcare, Inc.

(CCRN) is the lower-risk stock at 0. 78β versus Guardian Pharmacy Services, Inc. 's 1. 04β — meaning GRDN is approximately 34% more volatile than CCRN relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 17% for Guardian Pharmacy Services, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Guardian Pharmacy Services, Inc.

(GRDN) is pulling ahead at 17. 9% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: Guardian Pharmacy Services, Inc. grew EPS 144. 1% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Over a 3-year CAGR, GRDN leads at 16. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Guardian Pharmacy Services, Inc.

(GRDN) is the more profitable company, earning 3. 4% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps 3. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GRDN leads at 6. 1% versus -0. 3% for CCRN. At the gross margin level — before operating expenses — GRDN leads at 19. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Guardian Pharmacy Services, Inc.

(GRDN) trades at 29. 6x forward P/E versus 133. 8x for Cross Country Healthcare, Inc. — 104. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GRDN: 4. 7% to $38. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cross Country Healthcare, Inc.

(CCRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 78)). Both have compounded well over 10 years (CCRN: -10. 5%, GRDN: +126. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GRDN is a small-cap high-growth stock; CCRN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.